Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Verismo Therapeutics logo — The team that invented the first FDA-approved CAR-T therapy...

Verismo Therapeutics

The team that invented the first FDA-approved CAR-T therapy is back to revolutionize the space with the KIR-CAR.

Founded 2020 United States Philadelphia, United States 31 employees Seed Total: $40.00M Biotechnology, Health Care +1

General Information

Company Name Verismo Therapeutics
Founded Year 2020
Location United States Philadelphia, United States +1
Founders / Decision Makers
Team member Team member
Employees 31
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Seed
Social

Get notified when Verismo Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Verismo Therapeutics

Verismo Therapeutics is a biotechnology startup founded in 2020, headquartered in the United States. The company's mission, as reflected in their slogan "The team that invented the first FDA-approved CAR-T therapy is back to revolutionize the space with the KIR-CAR," is to pioneer the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, particularly targeting non-hematologic malignancies with limited treatment options. Verismo Therapeutics' innovative approach is centered around the development of SynKIR™-T cells, which are created by introducing KIR-based CARs (KIR-CARs) into T cells. These CARs are uniquely engineered to closely mimic the natural multichain design of killer immunoglobulin-like receptors (KIRs), a crucial family of immunologic receptors utilized by T cells and NK cells. The startup recently secured a significant milestone by closing a $17.00M Seed Round investment on 18 July 2023, with DongKoo Bio&Pharma and Hong Leong Bank participating as key investors. This substantial injection of funds not only underscores investor confidence in Verismo Therapeutics' pioneering approach but also provides the necessary capital to advance their groundbreaking technology. The company's preclinical studies have shown promising results, demonstrating that their KIR-CARs more effectively eliminate aggressive tumors in vivo compared to existing FDA-approved CAR-T cell therapies. Verismo Therapeutics operates at the intersection of biotechnology and health care, aiming to address critical unmet medical needs in the field of cancer immunotherapy through their innovative CAR-T cell technology. With this recent investment, the company is poised to further propel its research and development efforts, potentially reshaping the landscape of cancer treatment.

Taxonomy: Verismo Therapeutics, CAR-T therapy, KIR-CAR, chimeric antigen receptors, cellular immunotherapy, solid tumors, pancreatic cancer, mesothelioma, ovarian cancer, immuno-oncology, T-cell exhaustion, SynKIR, preclinical development, FDA-approved, immunologic receptors

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 2 •••• •••• 18 Jul 2023
Seed Round •••••• 1 •••• •••• 28 Feb 2023
Seed Round •••••• - 27 Apr 2021

Verismo Therapeutics Alternatives & Competitors

Verismo Therapeutics vs
Thunder Biotech
Thunder Biotech United States

MOTO-CAR®s: Innovative macrophage technology designed to provide effective treatment for patients wi...

Debt Financing
15 employees
Biotechnology, Pharmaceutical
Compare Verismo Therapeutics vs Thunder Biotech
Verismo Therapeutics vs
Adicet Bio, Inc
Adicet Bio, Inc United States

A biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell...

IPO
124 employees
Biopharma, Biotechnology
Compare Verismo Therapeutics vs Adicet Bio, Inc
Verismo Therapeutics vs
Atara Biotherapeutics
Atara Biotherapeutics United States

Pioneering off-the-shelf, allogeneic T-cell immunotherapies

112 employees
Also compare with: Verismo Therapeutics vs Currus Biologics Pty Ltd Currus Biologics Pty Ltd

FAQ About Verismo Therapeutics

The team that invented the first FDA-approved CAR-T therapy is back to revolutionize the space with the KIR-CAR.
Verismo Therapeutics was founded in 2020.
Verismo Therapeutics is headquartered in Philadelphia, United States.
Verismo Therapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Verismo Therapeutics has approximately 31 employees.
Verismo Therapeutics has completed 3 funding rounds, raising a total of $40.00M. The latest funding stage is Seed.
Top alternatives and competitors to Verismo Therapeutics include Thunder Biotech, Adicet Bio, Inc, Atara Biotherapeutics, Currus Biologics Pty Ltd, Link Cell Therapies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Verismo Therapeutics and Thunder Biotech are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Verismo Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes